Edition:
India

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

16.75USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$16.75
Open
$16.65
Day's High
$17.05
Day's Low
$16.60
Volume
63,194
Avg. Vol
120,254
52-wk High
$30.35
52-wk Low
$13.20

Chart for

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.50
Market Cap(Mil.): $636.74
Shares Outstanding(Mil.): 38.01
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): 9.88 28.66 32.90
EPS (TTM): 1.69 -- --
ROI: 4.59 13.20 12.74
ROE: 11.11 14.95 14.64

BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80

* LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS

08 May 2018

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

07 May 2018

BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board

* LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:

30 Apr 2018

BRIEF-Lannett Company Files For Potential Mixed Shelf Offering

* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage:

14 Feb 2018

BRIEF-Lannett Co Reports Q2 Earnings Per Share $0.37

* LANNETT ANNOUNCES FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS; REPORTS RECORD REVENUES, STRONG EARNINGS

08 Feb 2018

BRIEF-Lannett Co Voluntarily Pays Down $25 Mln Of Term Loans

* LANNETT COMPANY SAYS $25 MILLION PAY DOWN OF TERM LOANS WILL SAVE CO ABOUT $1.7 MILLION IN ANNUALIZED CASH INTEREST EXPENSE, AT CURRENT RATES Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Lannett Enters Into Consulting Agreement With Former CEO, Bedrosian

* LANNETT ENTERS INTO CONSULTING AGREEMENT WITH FORMER CEO, ARTHUR BEDROSIAN

01 Feb 2018

BRIEF-Lannett Names Timothy Crew To Board Of Directors

* LANNETT COMPANY INC - ‍ WITH CREW'S APPOINTMENT, TOTAL NUMBER OF DIRECTORS IS SEVEN​ Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Lannett Appoints Timothy Crew As CEO

* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY

21 Dec 2017

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

01 Dec 2017

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $105.60 -0.63
Pfizer Limited (PFIZ.NS) Rs2,379.60 --
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs1,954.35 --

Earnings vs. Estimates